Ordinary Index Rebalancing in the Solactive China Biotech Innovation Index | November 2021

In the ordinary rebalance the following composition will be implemented effective open 15.11.2021:

3SBIO INC
ALPHAMAB ONCOLOGY
ANHUI ANKE BIOTECHNOLOGY G-A
ASCENTAGE PHARMA GROUP INTERNATIONAL
BEIGENE LTD-ADR
BEIJING BOHUI INNOVATION B-A
BEIJING SL PHARMACEUTICAL -A
BEIJING TIANTAN BIOLOGICAL-A
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO LTD
BERRY GENOMICS CO LTD-A
BGI GENOMICS CO LTD-A
CHANGCHUN HIGH & NEW TECH-A
CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO LTD
DAAN GENE CO LTD-A
FUJIAN ANJOY FOODS CO LTD
GENSCRIPT BIOTECH CORP
GETEIN BIOTECH INC-A
GUANGDONG HYBRIBIO BIOTECH-A
HUALAN BIOLOGICAL ENGINEER-A
JOINN LABORATORIES CHINA CO LTD
JW CAYMAN THERAPEUTICS CO LT
KINTOR PHARMACEUTICAL LTD
LIAONING CHENG DA CO LTD
PHARMABLOCK SCIENCES NANJI-A
SHANGHAI HAOHAI BIOLOGICAL-A
SHANGHAI RAAS BLOOD PRODUC-A
SHENZHEN KANGTAI BIOLOGICA-A
SHENZHEN NEPTUNUS BIOENG-A
SHENZHEN WEIGUANG BIOLOGIC-A
SICHUAN KELUN PHARMACEUTIC-A
SINO BIOPHARMACEUTICAL LTD ORD
VIVA BIOTECH HOLDINGS
WALVAX BIOTECHNOLOGY CO-A
WUXI BIOLOGICS CAYMAN INC
ZAI LAB LTD
ZHEJIANG WOLWO BIO-PHARMAC-A